Core Viewpoint - GE Healthcare is committed to the Chinese market, emphasizing its strategic importance and denying rumors of selling its business in China. The company has taken concrete actions to reinforce its presence, including significant investments in local R&D and production facilities [2][3]. Group 1: Strategic Actions - GE Healthcare has established the East Hemisphere Headquarters Innovation Center for MRI in Tianjin, marking it as the only system-level MRI R&D base outside the U.S. The company plans to invest 500 million yuan over the next five years for high-end MRI equipment localization [2]. - The company has adjusted its strategy in China to focus on "precision cultivation," which includes organizational restructuring and layoffs in non-core positions, affecting less than 5% of the total workforce [2][3]. Group 2: Recruitment Strategy - GE Healthcare maintains a "reduction and increase" recruitment strategy, with approximately 150 positions open in China since 2025, primarily in R&D, production, and digitalization sectors [3]. Group 3: Localization and Production - GE Healthcare has developed the largest production base in China, with six major production sites and seven factories across various cities. The Beijing base has achieved over 50% localization for MRI core components, while the Shanghai Zhangjiang factory produces 60% of global contrast agents [5]. - The company has launched the first phase of its Precision Medicine Industrialization Base in July 2025, focusing on high-end nuclear medicine production and key component localization [5]. Group 4: R&D Focus - R&D is a core component of GE Healthcare's strategy in China, with increased investments since 2025. The Tianjin MRI Innovation Center will focus on core components and cutting-edge AI technology [6]. - The Ver sana series ultrasound devices, developed in Wuxi, feature AI-assisted diagnostic systems, achieving over 60,000 units shipped globally in the first eight months of 2025 [6]. Group 5: Market Strategy - GE Healthcare has shifted its market strategy to focus on "replacement demand" as the Chinese market transitions from new equipment installation to equipment replacement. The company offers high-end CT/MR replacement solutions emphasizing precision, lower radiation doses, and efficient workflows [7]. - The company is also targeting grassroots healthcare through products like the Ver sana series ultrasound devices and the Precision Medicine Industrialization Base, addressing the need for local healthcare solutions [7].